Jenburkt Pharmaceuticals: Standalone Unaudited Financial Results for the quarter and half year ended on 30th September, 2026
Jenburkt Pharmaceuticals (JENBURPH) filed a disclosure titled "Standalone Unaudited Financial Results for the quarter and half year ended on 30th September, 2026". The company is valued at about ₹395 crore.
What happened
Jenburkt Pharmaceuticals (JENBURPH) filed a disclosure with the exchanges on 3 November 2026 at 05:56 PM titled "Standalone Unaudited Financial Results for the quarter and half year ended on 30th September, 2026".
Company snapshot
Jenburkt Pharmaceuticals is a micro-cap company, with a market value of about ₹395 crore.
The stock last traded at ₹894, against a 52-week range of ₹845–₹1,073.9 (16.8% below the high).
Before this filing the shares had moved −5.3% over the month. Average daily turnover over the last 20 sessions was about ₹0.2 crore.
Promoters held 46.62% at the end of Q1 FY27, down 0.02% points from the previous quarter.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 36 | 7.8 | 17.66 |
| Q2 FY26 | 46 | 10.2 | 23.03 |
| Q3 FY26 | 43 | 5.9 | 13.44 |
| Q4 FY26 | 45 | 10.9 | 24.58 |
| Q1 FY27 | 36 | 5.9 | 13.34 |
What history shows
BCEIE has no earlier results filing from this company on record since May 2026.
Market-wide, 10,321 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.